• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Articles by Marie Powers

Surrogate biomarkers are gaining in interest but development path is still foggy

April 24, 2015
By Marie Powers
WASHINGTON – The FDA has been under the gun to qualify more biomarkers that could help accelerate the development of targeted therapies and track the progression of various diseases.
Read More

Progress coming in amyotrophic lateral sclerosis, but rigorous studies needed

April 23, 2015
By Marie Powers
The community of individuals living with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, has endured many false hopes for promising therapies and is still waiting for the first disease-modifying drug.
Read More

Alnylam gains on 12-month open-label patisiran data in FAP patients

April 22, 2015
By Marie Powers
WASHINGTON – Alnylam Pharmaceuticals Inc. used the forum of the American Academy of Neurology's (AAN) 67th annual meeting to disclose 12-month data from its ongoing phase II open-label extension (OLE) study of patisiran to treat transthyretin (TTR)-mediated amyloidosis in patients with familial amyloidotic polyneuropathy (FAP).
Read More

Despite promising pipelines, 'still a role' for traditional MS therapies

April 21, 2015
By Marie Powers
Efforts to develop remyelinating therapies in multiple sclerosis (MS) might have stolen some of the headlines heading into the American Academy of Neurology's (AAN) 67th Annual Meeting in Washington, but there are still plenty of data on traditional approaches to MS treatment on hand this week – some 500 presentations altogether – beginning with a slew of posters unveiled today.
Read More

Alzheimer's dominates neurology landscape as global impact looms

April 20, 2015
By Marie Powers
The ginormous 67th American Academy of Neurology (AAN) annual meeting is in full swing, with more than 2,500 abstracts scheduled for presentation at scientific sessions during the week. If the emerging science abstracts – formerly called the "late-breakers" – are any indication, therapeutic advances targeting Alzheimer's disease (AD) will dominate conversations at AAN, although significant updates on approaches to treat epilepsy, multiple sclerosis and Parkinson's disease also are planned.
Read More

Amgen's Corlanor crosses finish line, but Repatha seen as bigger win

April 17, 2015
By Marie Powers
The FDA approved Corlanor (ivabradine) to reduce the risk of hospitalization for worsening heart failure (HF), marking the first win in Amgen Inc.'s small but ambitious cardiovascular (CV) franchise.
Read More

FDA approves first generic Copaxone, but will SCOTUS scuttle launch plans?

April 17, 2015
By Marie Powers
The FDA approved the first generic version of Copaxone (glatiramer acetate injection) to treat patients with relapsing forms of multiple sclerosis (MS), giving a green light to the abbreviated new drug application (ANDA) filed by Sandoz Inc. to market Glatopa (glatiramer acetate injection, formerly M356), formulated as a once-daily 20 mg/mL injection.
Read More

Heart-on-a-chip could improve drug screening, personalized medicine

April 16, 2015
By Marie Powers
Researchers at the University of California at Berkeley have developed the prototype of a better mousetrap for in vitro drug studies that could someday transform the screening of cardiovascular drug candidates. The ultimate goal is to replace the use of animals to screen drug candidates for safety and efficacy, reducing both the time and cost to speed therapies through the development pipeline.
Read More

Heart-on-a-chip could improve drug screening, personalized medicine

April 16, 2015
By Marie Powers
Researchers at the University of California at Berkeley have developed the prototype of a better mousetrap for in vitro drug studies that could someday transform the screening of cardiovascular drug candidates. The ultimate goal is to replace the use of animals to screen drug candidates for safety and efficacy, reducing both the time and cost to speed therapies through the development pipeline.
Read More

Anti-LINGO-1 no flash in the pan? Biogen's AON data look brighter

April 15, 2015
By Marie Powers
Top-line findings for Biogen Inc.'s anti-LINGO-1 monoclonal antibody candidate, BIIB033, that were released earlier this year gained a bit more credibility when additional data were disclosed today in advance of the company's presentations next week at the American Academy of Neurology's (AAN) 67th Annual Meeting in Washington.
Read More
Previous 1 2 … 83 84 85 86 87 88 89 90 91 … 168 169 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe